TickerFacts.

Compare

Twist Bioscience Corp vs ADMA Biologics, Inc. vs Adaptive Biotechnologies Corp vs Vericel Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearTwist Bioscience Corp
TWST		ADMA Biologics, Inc.
ADMA		Adaptive Biotechnologies Corp
ADPT		Vericel Corp
VCEL
Year ended2025-09-302025-12-312025-12-312025-12-31
Revenue$376.57M$510.17M$276.98M$276.26M
Revenue growth (YoY)+20.3%+19.6%+54.8%+16.5%
Gross margin50.7% (computed)57.4%74.2% (computed)74.4% (computed)
Operating margin-36.2%37.5%-20.6%4.0%
Net margin-20.6%28.8%-21.5%6.0%
Net income-$77.67M$146.93M-$59.50M$16.52M
EPS (Diluted)-$1.30$0.60-$0.39$0.32
Operating cash flow-$47.63M$50.40M-$45.99M$51.91M
Free cash flow-$75.63M$27.82M-$48.95M$24.75M
Cash & equivalents$183.05M$87.63M$70.50M$100.09M
Total assets$641.86M$624.24M$512.74M$487.97M
Total liabilities$168.90M$146.92M$287.74M$133.33M
Shareholders' equity$472.96M$477.32M$218.79M$354.64M
Return on year-end equity-16.4%30.8%-27.2%4.7%
Shares outstanding60.63M237.87M153.78M50.62M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearTwist Bioscience CorpADMA Biologics, Inc.Adaptive Biotechnologies CorpVericel Corp
Latest$376.57M
Ended 2025-09-30		$510.17M
Ended 2025-12-31		$276.98M
Ended 2025-12-31		$276.26M
Ended 2025-12-31
1 year earlier$312.97M
Ended 2024-09-30		$426.45M
Ended 2024-12-31		$178.96M
Ended 2024-12-31		$237.22M
Ended 2024-12-31
2 years earlier$245.11M
Ended 2023-09-30		$258.21M
Ended 2023-12-31		$170.28M
Ended 2023-12-31		$197.52M
Ended 2023-12-31
3 years earlier$203.56M
Ended 2022-09-30		$154.08M
Ended 2022-12-31		$185.31M
Ended 2022-12-31		$163.70M
Ended 2022-12-31
4 years earlier$132.33M
Ended 2021-09-30		$80.94M
Ended 2021-12-31		$154.34M
Ended 2021-12-31		$153.07M
Ended 2021-12-31